See more : PIOLAX, Inc. (5988.T) Income Statement Analysis – Financial Results
Complete financial analysis of Ventyx Biosciences, Inc. (VTYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ventyx Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Star Cement Limited (STARCEMENT.NS) Income Statement Analysis – Financial Results
- Hong Kong Economic Times Holdings Limited (HKGEF) Income Statement Analysis – Financial Results
- TravelSky Technology Limited (TSYHF) Income Statement Analysis – Financial Results
- Daeduck Co.,Ltd. (00806K.KS) Income Statement Analysis – Financial Results
- SBFC Finance Limited (SBFC.NS) Income Statement Analysis – Financial Results
Ventyx Biosciences, Inc. (VTYX)
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 941.00K | 470.00K | 30.00K | 0.00 | 0.00 |
| Gross Profit | -941.00K | -470.00K | -30.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 175.77M | 87.74M | 58.48M | 6.37M | 3.55M |
| General & Administrative | 32.23M | 25.40M | 8.67M | 684.00K | 628.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.23M | 25.40M | 8.67M | 684.00K | 628.00K |
| Other Expenses | 0.00 | 41.00K | -5.45M | -1.00K | -1.00K |
| Operating Expenses | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
| Cost & Expenses | 207.99M | 113.14M | 67.15M | 7.05M | 4.18M |
| Interest Income | 15.07M | 4.67M | 78.00K | 358.00 | 146.00 |
| Interest Expense | 0.00 | 0.00 | 99.00K | 358.00K | 146.00K |
| Depreciation & Amortization | 158.00K | 470.00K | 30.00K | 7.05M | 4.18M |
| EBITDA | -207.84M | -107.96M | -67.12M | 0.00 | -1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -207.99M | -113.14M | -67.15M | -7.05M | -4.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.03M | 4.71M | -16.60M | -21.12M | -147.00K |
| Income Before Tax | -192.96M | -108.43M | -83.75M | -28.17M | -4.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -470.00K | -5.38M | 358.00K | 146.00K |
| Net Income | -192.96M | -107.96M | -78.37M | -28.53M | -4.47M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.30 | -2.06 | -1.55 | -0.57 | -0.09 |
| EPS Diluted | -3.30 | -2.06 | -1.55 | -0.57 | -0.09 |
| Weighted Avg Shares Out | 58.54M | 52.47M | 50.41M | 50.30M | 50.30M |
| Weighted Avg Shares Out (Dil) | 58.54M | 52.47M | 50.41M | 50.30M | 50.30M |
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
Ventyx Biosciences Announces Departure of Chief Financial Officer
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Dow Edges Lower; Ventyx Biosciences Shares Plummet
Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further
Source: https://incomestatements.info
Category: Stock Reports